Literature DB >> 26928246

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Sarka Pospisilova1, Lesley-Ann Sutton2, Jitka Malcikova1, Eugen Tausch3, Davide Rossi4, Emili Montserrat5, Carol Moreno6, Kostas Stamatopoulos7, Gianluca Gaidano4, Richard Rosenquist2, Paolo Ghia8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26928246      PMCID: PMC4815716          DOI: 10.3324/haematol.2015.139246

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

Authors:  Davide Rossi; Michaela Cerri; Clara Deambrogi; Elisa Sozzi; Stefania Cresta; Silvia Rasi; Lorenzo De Paoli; Valeria Spina; Valter Gattei; Daniela Capello; Francesco Forconi; Francesco Lauria; Gianluca Gaidano
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

2.  Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.

Authors:  Lesley-Ann Sutton; Viktor Ljungström; Larry Mansouri; Emma Young; Diego Cortese; Veronika Navrkalova; Jitka Malcikova; Alice F Muggen; Martin Trbusek; Panagiotis Panagiotidis; Frederic Davi; Chrysoula Belessi; Anton W Langerak; Paolo Ghia; Sarka Pospisilova; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

Review 3.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

4.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Hossein Khiabanian; Valeria Spina; Carmela Ciardullo; Alessio Bruscaggin; Rosella Famà; Silvia Rasi; Sara Monti; Clara Deambrogi; Lorenzo De Paoli; Jiguang Wang; Valter Gattei; Anna Guarini; Robin Foà; Raul Rabadan; Gianluca Gaidano
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

5.  Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; John C Byrd; Steven E Coutre; Don M Benson; Ian W Flinn; Nina D Wagner-Johnston; Stephen E Spurgeon; Brad S Kahl; Celeste Bello; Heather K Webb; Dave M Johnson; Sissy Peterman; Daniel Li; Thomas M Jahn; Brian J Lannutti; Roger G Ulrich; Albert S Yu; Langdon L Miller; Richard R Furman
Journal:  Blood       Date:  2014-03-10       Impact factor: 22.113

6.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

7.  Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.

Authors:  Jitka Malcikova; Jana Smardova; Ludmila Rocnova; Boris Tichy; Petr Kuglik; Vladimira Vranova; Sona Cejkova; Miluse Svitakova; Hana Skuhrova Francova; Yvona Brychtova; Michael Doubek; Martin Brejcha; Martin Klabusay; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

8.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

9.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Authors:  P Baliakas; A Hadzidimitriou; L-A Sutton; D Rossi; E Minga; N Villamor; M Larrayoz; J Kminkova; A Agathangelidis; Z Davis; E Tausch; E Stalika; B Kantorova; L Mansouri; L Scarfò; D Cortese; V Navrkalova; M J J Rose-Zerilli; K E Smedby; G Juliusson; A Anagnostopoulos; A M Makris; A Navarro; J Delgado; D Oscier; C Belessi; S Stilgenbauer; P Ghia; S Pospisilova; G Gaidano; E Campo; J C Strefford; K Stamatopoulos; R Rosenquist
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

10.  Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.

Authors:  J Malcikova; K Stano-Kozubik; B Tichy; B Kantorova; S Pavlova; N Tom; L Radova; J Smardova; F Pardy; M Doubek; Y Brychtova; M Mraz; K Plevova; E Diviskova; A Oltova; J Mayer; S Pospisilova; M Trbusek
Journal:  Leukemia       Date:  2014-10-28       Impact factor: 11.528

View more
  6 in total

Review 1.  The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.

Authors:  Gianluca Gaidano; Davide Rossi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Authors:  Lesley-Ann Sutton; Emma Young; Panagiotis Baliakas; Anastasia Hadzidimitriou; Theodoros Moysiadis; Karla Plevova; Davide Rossi; Jana Kminkova; Evangelia Stalika; Lone Bredo Pedersen; Jitka Malcikova; Andreas Agathangelidis; Zadie Davis; Larry Mansouri; Lydia Scarfò; Myriam Boudjoghra; Alba Navarro; Alice F Muggen; Xiao-Jie Yan; Florence Nguyen-Khac; Marta Larrayoz; Panagiotis Panagiotidis; Nicholas Chiorazzi; Carsten Utoft Niemann; Chrysoula Belessi; Elias Campo; Jonathan C Strefford; Anton W Langerak; David Oscier; Gianluca Gaidano; Sarka Pospisilova; Frederic Davi; Paolo Ghia; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

3.  Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.

Authors:  L Kazianka; C Drucker; C Skrabs; W Thomas; T Melchardt; S Struve; M Bergmann; P B Staber; E Porpaczy; C Einberger; M Heinz; A Hauswirth; M Raderer; I Pabinger; R Thalhammer; A Egle; C-M Wendtner; G Follows; G Hoermann; P Quehenberger; B Jilma; U Jaeger
Journal:  Leukemia       Date:  2016-11-02       Impact factor: 11.528

Review 4.  TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Authors:  Elias Campo; Florence Cymbalista; Paolo Ghia; Ulrich Jäger; Sarka Pospisilova; Richard Rosenquist; Anna Schuh; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2018-11-15       Impact factor: 9.941

Review 5.  Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods.

Authors:  Maria de Lourdes L F Chauffaille; Ilana Zalcberg; Wolney Gois Barreto; Israel Bendit
Journal:  Hematol Transfus Cell Ther       Date:  2020-06-25

6.  Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions.

Authors:  Anna Puiggros; Rosa Collado; Maria José Calasanz; Margarita Ortega; Neus Ruiz-Xivillé; Alfredo Rivas-Delgado; Elisa Luño; Teresa González; Blanca Navarro; MaDolores García-Malo; Alberto Valiente; José Ángel Hernández; María Teresa Ardanaz; María Ángeles Piñan; María Laura Blanco; María Hernández-Sánchez; Ana Batlle-López; Rocío Salgado; Marta Salido; Ana Ferrer; Pau Abrisqueta; Eva Gimeno; Eugènia Abella; Christelle Ferrá; María José Terol; Francisco Ortuño; Dolors Costa; Carol Moreno; Félix Carbonell; Francesc Bosch; Julio Delgado; Blanca Espinet
Journal:  Oncotarget       Date:  2017-04-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.